

Almost Family, Inc. Steve Guenthner (502) 891-1000

FOR IMMEDIATE RELEASE

November 1, 2016

Almost Family Reports Third Quarter 2016 Results

Louisville, KY, November 1, 2016 – Almost Family, Inc. (Nasdaq: AFAM), a leading regional provider of home health nursing and personal care services, announced today its financial results for the quarter ended September 30, 2016.

Third Quarter Highlights (1):

- Record net service revenues of approximately \$160.4 million with record revenues in our PC and HCI segments
- GAAP EPS of \$0.52 per diluted share, down \$0.27 from a year ago, Adjusted EPS of \$0.66, up \$0.14 from a year ago
- GAAP net income of \$5.4 million, down \$2.4 million from a year ago, Adjusted net income of \$6.8 million, up \$1.7 million from a year ago
- Record Adjusted EBITDA of \$14.8 million, up 39% from a year ago
- Healthcare Innovations (HCI) segment recorded Medicare Shared Savings payment success fees from multiple ACOs, while performing over 21,000 in-home assessments and having nearly 122,000 ACO beneficiaries and 15 Accountable Care Organizations under contract
- Unusually high health insurance claims and a significant rate cut in Connecticut's Medicaid-sponsored behavioral health program reduced diluted EPS by \$0.06 and \$0.05, respectively
- A change in the Company's expected effective tax rate recognized in the current quarter increased diluted EPS by \$0.02
- Year to date operating cash flow of \$15.3 million
- On October 14, 2016, we signed a definitive agreement to acquire a controlling interest in the entity holding the home health and hospice assets of Community Health Systems, Inc.

Management Comments

William Yarmuth, Chairman and Chief Executive Officer, commented: "We're very pleased with the progress in our core home health business in the quarter where we continue to generate meaningful organic growth, while also working through the integration of our 2015 and 2016 acquisitions. In addition, we're especially pleased to report outstanding record results in our

⁽¹⁾ See Non-GAAP Financial Measures starting on page 12

healthcare innovations segment which is drawing increased attention as it makes significant strides in its earnings and developments. At the same time all of this has been accomplished, we also just recently announced entering into the nation's largest public company hospital-home health joint venture, enabling us, in a very strategic way, to continue our strong growth trajectory."

Steve Guenthner, President added: "Although it was somewhat masked by the acquisitions of certain agencies where we did not acquire accounts receivable, we had especially strong operating cash flows in the third quarter reducing days outstanding to 53, the lowest level in quite some time. Additionally, we were pleased to see the somewhat favorable final rule for Medicare reimbursement in 2017, continuing the comparatively favorable tone of regulators toward home health."

Yarmuth concluded: "As we move through the balance of 2016 and into 2017 our key focus will be the successful integration of our new strategic home health partnership with CHS, continuing our work on organic volume growth and improving the financial results of all our business units."

The Company noted that the third quarter typically marks the seasonally low-water point of its home health business in terms of admissions and the high point for HCI results due to the timing of accounting recognition for success fees under the Medicare Shared Savings Program for Accountable Care Organizations.

Third Quarter Financial Results

VN segment net revenues increased \$10.1 million to \$108.4 million from \$98.3 million in the prior year and total Medicare admissions grew by 5.3% to 23,030 from 21,876 primarily due to home health agencies acquired in late 2015 and the first half of 2016. VN segment contribution increased \$0.5 million, or 4.5%, to \$12.6 million, from \$12.1 million in the prior year period. Contribution margin as a percentage of revenue decreased from 12.3% to 11.6%. VN results in the current quarter were impacted by unusually high health insurance claims experience of about \$1 million which lowered diluted EPS by \$0.06. On a same-store basis, Medicare admissions outside of Florida grew by 3.2%, while Florida was marginally positive. The Company is continuing its efforts to improve the performance of its Florida business which currently account for approximately one-fourth of VN segment revenues as compared to one-third a year ago and one-half three years ago.

PC segment net revenues increased \$10.9 million or 35.2% to a record \$41.7 million in 2016 from \$30.8 million in 2015 primarily due to acquisitions. PC segment contribution decreased \$0.5 million as compared to the same period of last year, primarily due to a 20% rate cut in the State of Connecticut's Medicaid-sponsored behavioral health program which generated approximately \$2.6 million of revenue in the current quarter as compared to \$3.3 million in the same quarter last year on similar volumes. The Company is currently evaluating the on-going viability of this program under current reimbursement and regulations.

Healthcare Innovations (HCI) segment net revenues increased \$8.3 million to a record \$10.3 million, in 2016 from \$2.1 million in 2015. The Company's ACO-enablement operations recorded shared savings incentive revenue of \$4.3 million from multiple ACOs participating in the Medicare Shared Savings Program. ACOs managed by the Company saved the Medicare program a total of \$25 million in the measurement period. The Company's assessment business acquired in transactions in

January 2016 and July 2015 contributed the balance of the revenues. As a result, operating income for the HCI segment was a record \$5.1 million, or \$0.15 per share attributable to Almost Family.

Corporate expenses as a percentage of revenue declined to 4.4%, from 4.8% in the prior year period. Deal, transition and other costs grew to \$2.3 million for 2016, primarily as a result of costs related to 2016 and 2015 acquisitions, while the prior year included a one-time \$4.2million benefit related to legal settlements. Borrowings related to acquisitions increased interest expense to \$1.4 million, from \$0.6 million in the prior year period.

Net cash from operating activities of \$4.9 million was generated in the third quarter of 2016. Home Health accounts receivable days sales outstanding were 53 at the end of the third quarter of 2016 as compared to 58 at the end of the third quarter of 2015. The Company noted that its late June 2016 acquisition of certain home health agencies from ResCare did not include accounts receivable. Building normal accounts receivable reduced operating cash flows by about \$6 million in the third quarter of 2016.

The effective tax rate for the third quarter of 2016 and 2015 was 37.3% and 21.0%, respectively. During the quarter the Company lowered its estimated effective tax rate from 40.5% to 39.5% due to lower permanently non-deductible expenses in relation to taxable income.

Year to Date Financial Results

VN segment net revenues increased \$33.0 million to a record \$328.7 million from \$295.6 million in the prior year period and total Medicare admissions grew by 2.4% to 70,021 from 68,380 primarily due to home health agencies acquired in late 2015 and 2016. VN segment contribution increased \$5.9 million, or 16.1%, to \$42.9 million, from \$37.0 million in the same period last year. Contribution margin as a percentage of revenue increased to 13.1% from 12.5%. On a same-store basis, Medicare admissions outside of Florida grew organically by 3% while Florida was down 4%.

PC segment net revenues increased \$32.0 million or 35.9% to a record \$121.1 million in 2016 from \$89.1 million in 2015 primarily due to acquisitions. PC segment contribution decreased 3.2% or \$0.3 million due to rate cuts in certain skilled elements of the Connecticut and Ohio Medicaid programs more than offset earnings from acquisitions.

HCI segment net revenues increased \$18.0 million to a record \$20.3 million, in 2016 from \$2.3 million in 2015, as acquired LTS and Ingenios assessment business revenues were \$15.4 million with the remainder due to higher shared savings revenue as multiple Imperium served ACOs received Medicare shared savings payments. LTS was acquired in January 2016 and Ingenios was acquired in July 2015. The HCI segment contribution thus improved \$5.5 million, as the segment was profitable for year to date 2016.

Corporate expenses as a percentage of revenue declined to 4.6%, from 5.2% in the prior year period. Deal, transition and other costs grew to \$7.5 million for 2016, primarily as a result of costs related to 2016 and 2015 acquisitions, while the prior year included a one-time \$4.2million benefit related to legal settlements. Borrowings related to acquisitions increased interest expense to \$4.3 million, from \$1.5 million in the same period 2015.

Net cash from operating activities of \$15.3 million was generated in 2016, up \$2.0 million from the \$13.3 million generated in the same period 2015.

The effective tax rate for 2016 and 2015 was 39.3% and 32.9%, respectively.

The Company noted that it will continue to pursue quality acquisitions of in-home health care service providers consistent with its stated strategy and the types of services its segments currently provide.

Acquisition of the Home Health and Hospice Assets of Community Health Systems, Inc.

On October 14, 2016, the Company signed a definitive agreement to acquire a controlling interest in the entity holding the home health and hospice assets of Community Health Systems, Inc. for \$128.0 million, subject to a working capital adjustment. Financing for the transaction has been fully committed by JPMorgan. The transaction is expected to be completed during the fourth quarter, subject to regulatory approvals and the satisfaction of customary closing conditions. The Company expects the transaction will add approximately \$200 million in revenue, all of which will be classified in the Company's VN segment. The transaction will expand the Company's geographic service territory to a total of 26 states.

Medicare Program Developments

On October 31, 2016 the Centers for Medicare and Medicaid Services (CMS) released the final rule for FY2017 home health reimbursement. The impact table included in the final rule suggests the final rule is slightly more favorable than the preliminary rule published earlier this year.

ALMOST FAMILY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) (UNAUDITED)

	Three montl	ns ended	Nine months ended			
	September 30, 2016	October 2, 2015	September 30, 2016	October 2, 2015		
Net service revenues	\$ 160,421	\$ 131,232	\$ 470,114	\$ 386,997		
Cost of service revenues (excluding						
depreciation & amortization)	86,074	69,475	251,998	204,134		
Gross margin	74,347	61,757	218,116	182,863		
General and administrative expenses:						
Salaries and benefits	42,952	36,767	126,134	108,993		
Other	18,167	15,598	56,323	47,772		
Deal and transition costs	2,257	(1,306)	7,455	(696)		
Total general and administrative expenses	63,376	51,059	189,912	156,069		
Operating income	10,971	10,698	28,204	26,794		
Interest expense, net	(1,399)	(559)	(4,335)	(1,463)		
Income before income taxes	9,572	10,139	23,869	25,331		
Income tax expense	(3,194)	(2,078)	(9,120)	(8,458)		
Net income	6,378	8,061	14,749	16,873		
Net loss - noncontrolling interests	(1,012)	(262)	(689)	330		
Net income attributable to Almost Family,						
Inc.	\$ 5,366	\$ 7,799	\$ 14,060	\$ 17,203		
Per share amounts-basic:						
Average shares outstanding	10,172	9,604	10,150	9,432		
Net income attributable to Almost Family,						
Inc.	\$ 0.53	\$ 0.81	\$ 1.39	\$ 1.82		
Per share amounts-diluted:						
Average shares outstanding	10,310	9,822	10,328	9,649		
Net income attributable to Almost Family,						
Inc.	\$ 0.52	\$ 0.79	\$ 1.36	\$ 1.78		

ALMOST FAMILY, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands)

CURRENT ASSETS: Cash and cash equivalents \$ 6.827 \$ 7.522 Accounts receivable - net 95,616 92,909 Prepaid expenses and other current assets 14,090 9,033 TOTAL CURRENT ASSETS 116,533 109,464 PROPERTY AND EQUIPMENT - NET 9,753 10,000 GOODWILL 320,794 277,061 GOODWILL 320,794 346,629 GOOWILL 320,794 346,629 GOOWILL 320,794 346,69 GOOWILL 320,794 346,		ember 30, 2016 NAUDITED)	January 1, 2016		
Cash and cash equivalents \$ 6,827 \$ 7,522 Accounts receivable - net 95,616 92,909 Prepaid expenses and other current assets 14,000 9,033 TOTAL CURRENT ASSETS 116,533 109,464 PROPERTY AND EQUIPMENT - NET 9,753 10,000 GOODWILL 320,794 277,061 OTHER INTANGIBLE ASSETS 69,99 64,629 OTHER ASSETS 4,143 3,615 TOTAL ASSETS \$ 521,132 \$ 464,769 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES \$ 14,007 11,297 Accrued other liabilities 36,054 40,742 Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES \$ 133,824 113,790 ERvolving credit facility 133,824 113,790 Deferred tax liabilities 6,335 5,390 Other liabilities 6,335 5,390 Other liabilities 6,335 5,390 TOTAL LIABILITIES 2,256<					
Accounts receivable - net 95,616 92,909 Prepaid expenses and other current assets 14,090 9,033 TOTAL CURRENT ASSETS 116,533 10,046 PROPERTY AND EQUIPMENT - NET 9,753 10,000 GOODWILL 320,794 277,061 OTHER INTANGIBLE ASSETS 69,099 64,629 OTHER RASSETS 4,143 3,615 TOTAL ASSETS \$ 521,132 \$ 464,769 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable \$ 14,007 \$ 11,297 Accounts payable \$ 14,007 \$ 11,297 Account dother liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES \$ 133,824 113,790 ERevolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 2,256 3,639 TOTAL LONG-TERM LIABILITIES 171,53 138,830 <td< td=""><td></td><td></td><td></td><td></td></td<>					
Prepaid expenses and other current assets 14,000 9,033 TOTAL CURRENT ASSETS 116,533 109,046 PROPERTY AND EQUIPMENT - NET 9,753 10,000 GOODWILL 320,794 277,061 OTHER INTANGIBLE ASSETS 69,909 64,629 OTHER ASSETS 4,143 3,615 TOTAL ASSETS \$ 521,132 \$ 464,769 CURRENT LIABILITIES **** CURRENT LIABILITIES** Accrued other liabilities 36,054 40,742 *** TOTAL CURRENT LIABILITIES** \$ 133,824 113,790 ***** Coloring credit facility 133,824 113,790 Deferred tax liabilities 13,844 13,094 Seller notes 12,500 6,556 Other liabilities 5,335 5,300 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 22,121 190,869 **** COLORING TOTAL LIABILITIES 2,256 3,639 *** COLORING TOTAL LIABILITIES 2,256 3,639 <td co<="" td=""><td></td><td>\$ 6,827</td><td>\$</td><td>7,522</td></td>	<td></td> <td>\$ 6,827</td> <td>\$</td> <td>7,522</td>		\$ 6,827	\$	7,522
TOTAL CURRENT ASSETS		95,616		92,909	
PROPERTY AND EQUIPMENT - NET 9,753 10,000 GOODWILL 320,794 277,061 OTHER INTANGIBLE ASSETS 69,909 64,629 OTHER ASSETS 4,143 3,615 TOTAL ASSETS \$ 521,132 \$ 464,769 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable \$ 14,007 \$ 11,297 Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES \$ 50,061 \$ 52,039 LONG-TERM LIABILITIES Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 25,	Prepaid expenses and other current assets	 14,090		9,033	
GOODWILL 320,794 277,061 OTHER NTANGIBLE ASSETS 69,909 64,629 OTHER ASSETS 4,143 3,615 TOTAL ASSETS \$ 521,132 \$ 464,769 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable \$ 14,007 \$ 11,297 Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES: \$ 50,061 52,039 LONG-TERM LIABILITIES: \$ 133,824 113,790 Deferred tax liabilities 18,494 13,090 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 25,000; 10,489 and 10,125 5 5 issued and outstanding		116,533		109,464	
OTHER INTANGIBLE ASSETS 69,909 64,629 OTHER ASSETS 4,143 3,615 TOTAL ASSETS \$ 521,132 \$ 464,769 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable \$ 14,007 \$ 11,297 Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES \$ 50,061 52,039 LONG-TERM LIABILITIES: \$ 133,824 113,790 Revolving credit facility 133,824 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000; hares; none issued or outstanding 1,050 1,013 Treasury stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 1,050 1,013 Treasury stock, par value \$0.10; authorized 25,000; 10,489 and 10,125	PROPERTY AND EQUIPMENT - NET	9,753			
OTHER ASSETS 4,143 3,615 TOTAL ASSETS \$ 521,132 464,769 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable \$ 14,007 \$ 11,297 Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES: \$ 20,001 52,009 LONG-TERM LIABILITIES: \$ 133,824 113,790 Revolving credit facility 13,844 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 2,256 3,639 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 25,000; 10,489 and 10,125 1,013 1,013 Freferred stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 1,013 1,013 1,013 Teasury stock, at cost, 116 and 103 shares 3,01 1,013<					
TOTAL ASSETS \$ 521,132 \$ 464,769		69,909			
LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: \$ 14,007 \$ 11,297 Accounts payable Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES 50,061 52,039 LONG-TERM LIABILITIES: \$ 133,824 113,790 Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 21,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730	OTHER ASSETS	4,143		3,615	
CURRENT LIABILITIES: Accounts payable	TOTAL ASSETS	\$ 521,132	\$	464,769	
CURRENT LIABILITIES: Accounts payable					
Accounts payable \$ 14,007 \$ 11,297 Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES 50,061 52,039 LONG-TERM LIABILITIES: Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — STOCKHOLDERS' EQUITY: — — Common stock, par value \$0.05; authorized 25,000; 10,489 and 10,125 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766)	LIABILITIES AND STOCKHOLDERS' EQUITY				
Accrued other liabilities 36,054 40,742 TOTAL CURRENT LIABILITIES 50,061 52,039 LONG-TERM LIABILITIES: Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - 4 190,869 NONCONTROLLING INTEREST - REDEEMABLE - 4 2,256 3,639 STOCKHOLDERS' EQUITY: 5 2,256 3,639 STOCKHOLDERS' EQUITY: 5 4 -	CURRENT LIABILITIES:				
TOTAL CURRENT LIABILITIES 50,061 52,039 LONG-TERM LIABILITIES: Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE -		\$ 14,007	\$	11,297	
CONG-TERM LIABILITIES: Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	Accrued other liabilities	 36,054		40,742	
Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - 4 190,869 NONCONTROLLING INTEREST - REDEEMABLE - 4 2,256 3,639 STOCKHOLDERS' EQUITY: 5 2,256 3,639 STOCKHOLDERS' EQUITY: - - - - Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding -	TOTAL CURRENT LIABILITIES	50,061		52,039	
Revolving credit facility 133,824 113,790 Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - 4 190,869 NONCONTROLLING INTEREST - REDEEMABLE - 4 2,256 3,639 STOCKHOLDERS' EQUITY: 5 2,256 3,639 STOCKHOLDERS' EQUITY: - - - - Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding -	LONG TERM LIADII ITIES.				
Deferred tax liabilities 18,494 13,094 Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261		122 024		112 700	
Seller notes 12,500 6,556 Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	•				
Other liabilities 6,335 5,390 TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261					
TOTAL LONG-TERM LIABILITIES 171,153 138,830 TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261					
TOTAL LIABILITIES 221,214 190,869 NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: 2,256 3,639 STOCKHOLDERS' EQUITY: - - Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding - - Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261		 			
NONCONTROLLING INTEREST - REDEEMABLE - HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261		 			
HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	TOTAL LIABILITIES	221,214		190,869	
HEALTHCARE INNOVATIONS 2,256 3,639 STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	NONCONTROLLING INTEREST - REDEEMABLE -				
STOCKHOLDERS' EQUITY: Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261		2,256		3,639	
Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or outstanding — — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261		,		,	
outstanding — — Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	STOCKHOLDERS' EQUITY:				
Common stock, par value \$0.10; authorized 25,000; 10,489 and 10,125 issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	Preferred stock, par value \$0.05; authorized 2,000 shares; none issued or				
issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	outstanding	_		_	
issued and outstanding 1,050 1,013 Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261					
Treasury stock, at cost, 116 and 103 shares (3,214) (2,731) Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	•	1,050		1,013	
Additional paid-in capital 140,351 127,253 Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261		(3,214)		(2,731)	
Noncontrolling interest - nonredeemable (766) (730) Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261	·				
Retained earnings 160,241 145,456 TOTAL STOCKHOLDERS' EQUITY 297,662 270,261					
TOTAL STOCKHOLDERS' EQUITY 297,662 270,261					
		\$ 	\$		

ALMOST FAMILY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (In thousands)

	Nine Months Ended				
	September 30, 2016	October 2, 2015			
Cash flows of operating activities:					
Net income	\$ 14,749	\$ 16,873			
Adjustments to reconcile net income to net cash provided by					
operating activities:					
Depreciation and amortization	3,020	2,625			
Provision for uncollectible accounts	10,626	9,322			
Stock-based compensation	2,013	1,455			
Deferred income taxes	6,081	3,108			
	36,489	33,383			
Change in certain net assets and liabilities, net of the effects of acquisitions:					
Accounts receivable	(12,831)	(13,444)			
Prepaid expenses and other current assets	(4,451)	(4,038)			
Other assets	(620)	(46)			
Accounts payable and accrued expenses	(3,302)	(2,535)			
Net cash provided by operating activities	15,285	13,320			
Cash flows of investing activities:					
Capital expenditures	(4,364)	(1,753)			
Cost basis investment	(4,304)	(1,000)			
Acquisitions, net of cash acquired	(31,256)	(55,701)			
Net cash used in investing activities	(35,620)				
Net cash used in investing activities	(53,020)	(58,454)			
Cash flows of financing activities:					
Credit facility borrowings	215,430	163,904			
Credit facility repayments	(195,396)	(118,053)			
Debt issuance fees	(102)	(1,161)			
Proceeds from stock option exercises	(9)	141			
Purchase of common stock in connection with share awards	(484)	(338)			
Tax impact of share awards	257	227			
Payment of special dividend in connection with share awards	-	(50)			
Principal payments on notes payable and capital leases	(56)	(54)			
Net cash provided by financing activities	19,640	44,616			
Net change in cash and cash equivalents	(695)	(518)			
Cash and cash equivalents at beginning of period	7,522	6,886			
Cash and cash equivalents at organism of period	\$ 6,827	\$ 6,368			
Cash and Cash equivalents at end of period	φ 0,827	φ 0,308			

ALMOST FAMILY, INC. AND SUBSIDIARIES RESULTS OF OPERATIONS (UNAUDITED)

(In thousands)

			Three Mo					
	Septe	ember	30, 2016		October 2	2, 2015	Cha	nge
	Amoi	unt	% Rev	A	mount	% Rev	Amount	%
Home Health Operations								
Net service revenues:								
Visiting Nurse	\$ 108,	425	72.2%	\$	98,344	76.1%	\$ 10,081	10.3%
Personal Care	41,	688	27.8%		30,837	23.9%	10,851	35.2%
	150,	113	100.0%	1	29,181	100.0%	20,932	16.2%
Operating income before corporate expenses:				-				
Visiting Nurse	12,	618	11.6%		12,074	12.3%	544	4.5%
Personal Care	2,	540	6.1%		3,067	9.9%	(527)	-17.2%
	15,	158	10.1%		15,141	11.7%	17	0.1%
Healthcare Innovations Operations								
Revenue	10,	308	100.0%		2,051	100.0%	8,257	402.6%
Operating income	5,	051	49.0%		485	23.6%	4,566	941.4%
Corporate expenses	6,	981	4.4%		6,234	4.8%	747	12.0%
Deal, transition and other costs	2,	257	1.4%		(1,306)	-1.0%	3,563	-272.8%
Operating income	10,	971	6.8%		10,698	8.2%	273	2.6%
Interest expense, net	(1,	399)	-0.9%		(559)	-0.4%	(840)	150.3%
Income tax expense	(3,	194)	-2.0%		(2,078)	-1.6%	(1,116)	53.7%
Net income	\$ 6,	378	4.0%	\$	8,061	6.1%	\$ (1,683)	-20.9%
Adjusted EBITDA (1)	\$ 14,	804	9.2%	\$	10,623	8.1%	\$ 4,181	39.4%
Adjusted net income (1)	\$ 7,	793	4.9%	\$	5,361	4.1%	\$ 2,432	45.4%

⁽¹⁾ See Non-GAAP Financial Measures starting on page 12.

		Nine Mor				
	Septembe	er 30, 2016	October		Cha	ange
	Amount	% Rev	Amount	% Rev	Amount	%
Home Health Operations						
Net service revenues:						
Visiting Nurse	\$ 328,697	73.1%	\$ 295,627	76.8%	\$ 33,070	11.2%
Personal Care	121,074	26.9%	89,086	23.2%	31,988	35.9%
	449,771	100.0%	384,713	100.0%	65,058	16.9%
Operating income before corporate expenses:	'	-				
Visiting Nurse	42,905	13.1%	36,956	12.5%	5,949	16.1%
Personal Care	9,273	7.7%	9,580	10.8%	(307)	-3.2%
	52,178	11.6%	46,536	12.1%	5,642	12.1%
Healthcare Innovations Operations						
Revenue	20,343	100.0%	2,284	100.0%	18,059	790.7%
Operating income (loss)	5,098	25.1%	(434)	-19.0%	5,532	NM
Corporate expenses	21,617	4.6%	20,004	5.2%	1,613	8.1%
Deal, transition and other costs	7,455	1.6%	(696)	-0.2%	8,151	-1171.1%
Operating income	28,204	6.0%	26,794	6.9%	1,410	5.3%
Interest expense, net	(4,335)	-0.9%	(1,463)	-0.4%	(2,872)	196.3%
Income tax expense	(9,120)	-1.9%	(8,458)	-2.2%	(662)	7.8%
Net income	\$ 14,749	3.1%	\$ 16,873	4.4%	\$ (2,124)	-12.6%
Adjusted EBITDA (1)	\$ 40,486	8.6%	\$ 29,962	7.7%	\$ 10,524	35.1%
Adjusted net income (1)	\$ 19,259	4.1%	\$ 14,536	3.8%	\$ 4,723	32.5%

⁽¹⁾ See Non-GAAP Financial Measures starting on page 12.

VISITING NURSE SEGMENT OPERATING METRICS

		Th	ree Mont						
	S	eptember 30	, 2016	C	ctober 2,	2015		Chan	ige
		Amount	%	A	mount	%	A	mount	%
Average number of locations		169			164			5	3.0%
All payors:									
Patient months		88,396		:	80,940			7,456	9.2%
Admissions		25,788			24,759			1,029	4.2%
Billable visits		711,998		6	45,589		ć	56,409	10.3%
Medicare:									
Admissions		23,030	89%		21,876	88%		1,154	5.3%
Revenue (in thousands)	\$	101,383	94%	\$ 9	92,033	94%	\$	9,350	10.2%
Revenue per admission	\$	4,402		\$	4,207		\$	195	4.6%
Billable visits		630,089	88%	5	30,709	90%	4	19,380	8.5%
Recertifications		12,639			11,966			673	5.6%
Payor mix % of Admissions									
Traditional Medicare Episodic		84.0%			84.6%			-0.6%	
Replacement Plans Paid Episodically		5.9%			4.1%			1.8%	
Replacement Plans Paid Per Visit		10.1%			11.3%			-1.2%	
Non-Medicare:									
Admissions		2,758	11%		2,883	12%		\$ (125)	-4.3%
Revenue (in thousands)	\$	7,042	6%	\$	6,311	6%	\$	731	11.6%
Revenue per admission	\$	2,553		\$	2,189		\$	364	16.6%
Billable visits		81,909	12%	(54,880	10%	1	17,029	26.2%
Recertifications		1,233			774			459	59.3%
Payor mix % of Admissions									
Medicaid & other governmental		25.9%			30.6%			-4.7%	
Private payors		74.1%			69.4%			4.7%	

PERSONAL CARE SEGMENT OPERATING METRICS

	Three Month	ns Ended			
	September 30, 2016	October 2, 2015	Chan	nge	
	Amount	Amount	Amount	%	
Average number of locations	80	66	14	21.2%	
Admissions	2,638	1,725	913	52.9%	
Patient months of care	43,562	25,419	18,143	71.4%	
Billable hours	1,919,931	1,384,466	535,465	38.7%	
Revenue per billable hour	\$ 21.71	\$ 22.27	\$ (0.56)	-2.5%	

VISITING NURSE SEGMENT OPERATING METRICS

		Nin	e Month	ıs En	ded			
	Sept	ember 30, 2016			October 2, 2	2015	Chan	ige
		Amount	%		Amount	%	Amount	%
Average number of locations		165			162		3	1.9%
All payors:								
Patient months		270,880			242,989		27,891	11.5%
Admissions		81,574			75,958		5,616	7.4%
Billable visits		2,174,980			1,926,660		248,320	12.9%
Medicare:								
Admissions		70,021	86%		68,380	90%	1,641	2.4%
Revenue (in thousands)	\$	308,055	94%	\$	280,827	95%	\$ 27,228	9.7%
Revenue per admission	\$	4,399		\$	4,107		\$ 293	7.1%
Billable visits		1,921,796	88%		1,745,856	91%	175,940	10.1%
Recertifications		37,777			35,473		2,304	6.5%
Payor mix % of Admissions								
Traditional Medicare Episodic		82.5%			83.9%		-1.4%	
Replacement Plans Paid Episodically		5.2%			4.0%		1.2%	
Replacement Plans Paid Per Visit		12.3%			12.1%		0.2%	
Non-Medicare:								
Admissions		11,553	14%		7,578	10%	3,975	52.5%
Revenue (in thousands)	\$	20,642	6%	\$	14,800	5%	\$ 5,842	39.5%
Revenue per admission	\$	1,787		\$	1,953		\$ (166)	-8.5%
Billable visits		253,184	12%		180,804	9%	72,380	40.0%
Recertifications		3,517			1,485		2,032	136.8%
Payor mix % of Admissions					· · · · · · · · · · · · · · · · · · ·			
Medicaid & other governmental		41.1%			32.4%		8.7%	
Private payors		58.9%			67.6%		-8.7%	

PERSONAL CARE OPERATING METRICS

	Nine Month	s Ended			
	September 30, 2016	October 2, 2015	Change		
	Amount	Amount	Amount	%	
Average number of locations	74	64	10	15.6%	
Admissions	7,675	4,803	2,872	59.8%	
Patient months of care	122,380	71,907	50,473	70.2%	
Billable hours	5,575,254	3,989,328	1,585,926	39.8%	
Revenue per billable hour	\$ 21.72	\$ 22.33	\$ (0.61)	-2.8%	

HEALTHCARE INNOVATIONS SUPPLEMENTAL DATA

		Three Month	s Ended		
	Sej	2016	October 2, 2 015	Ch	ange
		Amount	Amount	Amount	%
In-home Assessments		21,019	1,962	19,057	NM
Medicare ACO enrollees under management		121,881	83,133	38,748	46.6%
ACOs under contract		15	11	4	36.4%
Assets	\$	64,556	11,070 \$	53,486	NM
Liabilities	\$	23,118	1,124 \$	21,994	NM
Non-controlling interest - redeemable	\$	2,256	3,639 \$	(1,383	-38.0%
Non-controlling interest - nonredeemable	\$	1,060	417 \$	643	154.2%
		Nine Mo	onths Ended		
	Se	ptember 30, 20	October 2,	2015	Change
		Amount	Amoun	t Amo	unt %
In-home Assessments		79,01	7 1,9	962 77,0	055 NM
Medicare enrollees under management		121,88	83,	133 38,7	48 46.6%
ACOs under contract		1	5	11	4 36.4%

Non-GAAP Financial Measures

The information provided in some of the tables in this release includes certain non-GAAP financial measures as defined under SEC rules. In accordance with SEC rules, the Company has provided, in the supplemental information, a reconciliation of those measures to the most directly comparable GAAP measures.

Adjusted Net Income and Adjusted Earnings Per Share

Adjusted net income and adjusted earnings per share is not a measure of financial performance under accounting principles generally accepted in the United States of America. It should not be considered in isolation or as a substitute for net income, operating income, cash flows from operating, investing or financing activities, or any other measure calculated in accordance with generally accepted accounting principles. The presentation of adjusted net income and adjusted earnings per share provides investors with pertinent information to enable comparison of financial performance between periods by excluding certain items that the Company believes are not representative of its ongoing operations due to the nature of the items.

The following tables set forth a reconciliation of net income attributable to Almost Family, Inc. to adjusted net income:

ALMOST FAMILY, INC. AND SUBSIDIARIES RECONCILIATION OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE (In thousands)

		Three Months Ended				Nine Months Ended			
(in thousands)	Septen	nber 30, 2016	Octo	ber 2, 2015	September 30, 2016		October 2, 2015		
Net income	\$	6,378	\$	8,061	\$	14,749	\$	16,873	
A 1 11 1									
Addbacks:									
Deal, transition and other, net of tax		1,415		(2,700)		4,510		(2,337)	
Adjusted net income		7,793		5,361		19,259		14,536	
Non-controlling interest		(1,012)		(262)		(689)		330	
Adjusted net income attributable to Almost									
Family, Inc.	\$	6,781	\$	5,099 \$	S	18,570	\$	14,866	
Per share amounts-diluted:									
		10.210		0.022		10.220		0.640	
Average shares outstanding		10,310		9,822		10,328		9,649	
Net income		0.62		0.82		1.43		1.75	
Addbacks:									
Deal, transition and other, net of tax		0.14		(0.27)		0.44		(0.24)	
Adjusted earnings per share		0.76		0.55		1.86		1.51	
Non-controlling interest		(0.10)		(0.03)		(0.07)		0.03	
Adjusted net income attributable to Almost									
Family, Inc.	\$	0.66	\$	0.52	\$	1.80	\$	1.54	
	_		_				- -		

Adjusted EBITDA

Adjusted earnings before interest, income tax, depreciation and amortization, amortization of stock-based compensation, deal, transition and other (Adjusted EBTIDA) is not a measure of financial performance under accounting principles generally accepted in the United States of America. It should not be considered in isolation or as a substitute for net income, operating income, cash flows from operating, investing or financing activities, or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA Operations are significant components in understanding and evaluating financial performance and liquidity. Management routinely calculates and communicates Adjusted EBITDA Operations and believes that it is useful to investors because it provides a common analytical indicator within our industry to evaluate performance, measure leverage capacity and debt service ability, and to estimate current or prospective enterprise value. Adjusted EBITDA is also used in certain covenants contained in our credit agreement.

The following tables set forth a reconciliation of net income from continuing operations to Adjusted EBITDA from Home Health Operations:

ALMOST FAMILY, INC. AND SUBSIDIARIES RECONCILIATION OF ADJUSTED EBITDA (In thousands)

		Three Mont	hs End	ed	Nine Months Ended				
(in thousands)	Septen	September 30, 2016 October 2, 2015		Septe	mber 30, 2016	October 2, 201			
Net income	\$	6,378	\$	8,061	\$	14,749	\$	16,873	
Add back:									
Interest expense		1,399		559		4,335		1,463	
Income tax expense		3,194		2,078		9,120		8,458	
Depreciation and amortization		964		781		2,814		2,409	
Stock-based compensation		612		450		2,013		1,455	
Deal and transition costs		2,257		(1,306)		7,455		(696)	
Adjusted EBITDA	\$	14,804	\$	10,623	\$	40,486	\$	29,962	

About Almost Family, Inc.

Almost Family, Inc., founded in 1976, is a leading regional provider of home health nursing services, with branch locations in Florida, Ohio, Tennessee, New York, Connecticut, Kentucky, New Jersey, Massachusetts, Pennsylvania, Georgia, Wisconsin, Indiana, Missouri, Illinois, Mississippi and Alabama (in order of revenue significance and prior to the acquisition of Community Health Systems, Inc. home health and hospice operations). Almost Family, Inc. and its subsidiaries operate a Medicare-certified segment, a personal care segment and a healthcare innovations segment. Almost Family operates over 250 branch locations in sixteen U.S. states.

Forward Looking Statements

All statements, other than statements of historical facts, included in this news release are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terminology such as "may," "will," "expect," "believe," "estimate," "project," "anticipate," "continue," or similar terms, variations of those terms or the negative of those terms. These forward-looking statements are based on the Company's current plans, expectations and projections about future events. Statements about the Company's or CHS Home Health's past financial results do not, and are not meant to, predict future results. The Company can provide no assurance that such results and performance will continue.

Because forward-looking statements involve risks and uncertainties, the Company's actual results could differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. The potential risks and uncertainties which could cause actual results to differ materially include: the satisfaction of the conditions precedent to the consummation of the proposed transaction, including, without limitation, the receipt of regulatory approvals or third party consents on the terms desired or anticipated; the Company's ability to obtain financing on the anticipated terms and schedule; disruptions of the Company's and CHS Home Health's current plans, operations and relationships caused by the announcement and pendency of the proposed transaction; the impact of further changes in healthcare reimbursement systems, including the ultimate outcome of potential changes to Medicare reimbursement for home health services and to Medicaid reimbursement due to state budget shortfalls; the ability of the Company to maintain its level of operating performance and achieve its cost control objectives; changes in our relationships with referral sources; unanticipated difficulties or expenditures relating to the proposed transaction, including, without limitation, difficulties that result in the failure to achieve expected synergies, efficiencies and cost savings from the proposed transaction within the expected time period (if at all); government regulation; health care reform; pricing pressures from Medicare, Medicaid and other third-party payers; changes in laws and interpretations of laws relating to the healthcare industry; the ability of the Company to integrate, manage and keep secure our information systems; changes in the marketplace and regulatory environment for Health Risk Assessments and the Company's self-insurance risks. For a more complete discussion regarding these and other factors which could affect the Company's financial performance, refer to the Company's various filings with the Securities and Exchange Commission, including its filing on Form 10-K for the fiscal year ended January 1, 2016, in particular information under the headings "Special Caution Regarding Forward-Looking Statements" and "Risk Factors." With regard to the Company's investment in development-stage enterprises in its Healthcare Innovations segment, there can be no assurance that its operational and developmental objectives will be realized or that the Company's investments will result in future returns. The Company undertakes no obligation to update or revise its forwardlooking statements.

####